1Per Olsson, 1David Hermann, 2Margareta Hammarlund-Udenaes, 2Mats O Karlsson A Population PK/PD model for the irreversible inhibition of 5alpha-reductase types 1 and 2, and the effects on plasma dihydrotestosterone levels.
|
Rik de Greef1, Helen Kastrissios PhD, Jean-Michel Gries PharmD,PhD, Lewis B. Sheiner, MD, Terrence F. Blaschke MD. The Use Of Compliance Data In The Analysis Of A Clinical Trial Of Antiretroviral Drugs In HIV+ Individuals
|
Namik Taright, France Mentré and Alain Mallet Non-Stationarity Of Kinetic Parameters In Multi-Occasion Designs
|
Jixian Wang Two-Stage Procedures For The Analysis Of Cross-Over Trials Using Pharmacokinetic And Pharmacodynamic Models
|
C. Veyrat-Follet1,2, E. Fuseau1, R. Farinotti1, J.L. Palmer2 Is Ipecac Model a good predictor of concentration-efficacy response to Ondansetron in patients?
|
Stuart Beal, Ph.D Analyzing Odd Type Data Using NONMEM
|
Adrian Dunne Population Analysis of Ordinal Categorical Data.
|
Jon Wakefield, Dave Lunn, Nicky Best, David Spiegelhalter The Bayesian Approach To Categorical Responses
|
Etienne Chatelut, Alan V. Boddy, François Doz Subsequent Developments Of Formulas Designed For Predicting Carboplatin Clearance In Adults And In Children
|
Michael Cole, Herbie Newell, Andrew Pearson, John Matthews, Alan Boddy Population Pharmacokinetics Of Etoposide In Children.
|
J.-L. Steimer, B. Fotteler, R. Gieschke, N. Buss, F. Hoffmann-La Roche Mixed-Effects Modelling Of The Dose-AUC Relationship Of Saquinavir Single Dose In Healthy Subjects
|
David J. Lunn & Leon Aarons The pharmacokinetics of saquinavir: a Markov chain, Monte Carlo population analysis
|
C. Anthony Hunt, Serge Guzy and Daniel L. Weiner A Paradigm For Validating Methodologies To Simulate Clinical Trials Validation Of Pharmacodynamic Predictions
|
Nicky Best, Andrew Thomas, David Lunn, Jon Wakefield and David Spiegelhalter New Developments In The BUGS Software For Bayesian Modelling
|
Gomeni R.(1), Mallet A.(2) and Gomeni C NPML-Fit: A Graphical Nonparametric Population Modelling Program
|
Niclas Jonsson and Mats Karlsson XPose 2.0 - An S-Plus Based Population Model Building Aid For NONMEM
|
Milligan P.1, Karlsson M.2, Nichols D. Experiences With Genotype And Phenotype Information In Mixed Effects Modelling
|
Niclas Jonsson Covariate Model Building In Population Analysis
|
Lutz Harnisch, Willi Weber,Hoechst Marion Roussel The Estimation Of Drug-Drug Interactions In Population Pharmacokinetic Trials
|
K. E. Fattinger and D. Verotta The Estimation Of Drug Input Rate Functions By Nonparametric Subject-Specific Population Deconvolution
|
Pascal Girard Under-Compliance And Population Pharmacokinetics
|
Mats O. Karlsson, E. Niclas Jonsson, Curtis Wiltse and Janet R. Wade Assumption Testing In Population Pharmacokinetic Models
|
Aarons, L. and Gupta, S. K A Mixed-Effects Modelling Approach To The Analysis Of Verapamil-GITS Blood Pressure Data
|
N. Bleyzac1,2 , F. Vial1 , B. Allard-Latour1 , J. Mouret1 , R W. Jelliffe2 , P. H. Maire1,2 Contribution Of Nonparametric Population Pharmacokinetic Software To The Determination Of Diurnal Variations Of Drug Pharmacokinetic Parameters
|
Dubruc C, *Mesnil F, Thenot JP, *Mentré F. Population Pharmacokinetic Analysis Of Mizolastine In Healthy Young Volunteers And Allergic Patients Using NONMEM
|
M.-E. Ebelin1, F. Mentré2, P. Burtin1, R. Laplanche3 1 Pharmacokinetic Population Analysis Of SDZ ENA 713 And Its Metabolite In Patients; Relationships With Efficacy, Safety And Tolerability
|
Frey, N., Laveille, C., Kiefer, Ph., Laudignon, N. And Jochemsen, R. Population Pharmacokinetics/Pharmacodynamics Of A New Formulation Of Gliclazide In 224 Type 2 Diabetics.
|
Garcia MJ, Santos Buelga D, Otero MJ, Serrano J, Blanco B, Dominguez-Gil A Population Pharmacokinetics: Effect Of Polytherapy On Valproic Acid Clearance
|
Niclas Jonsson and Mats Karlsson Covariate Model Building In Population Analysis Using A Bootstrap Resampling Procedure
|
Khan, A.Z.1, Pitsiu, M.1, Aarons, L.A2, Parivar, K.3, Widman, M3 Population Pharmacokinetic Analysis Of Eltanolone
|
Per Larsson, Eva Weibull, Astra Draco AB, Lund, Sweden, Søren Pedersen, Lone Agertoft, Estimation Of Bioavailability Using A Semi-Simultaneous Design
|
Laveille, C., Frey, N., Lerebours, G., Resplandy, G. And Jochemsen, R Population Pharmacokinetics-Pharmacodynamics Of A New Specific Bradycardic Agent (S 16257) And Its Metabolite (S 18982) Evaluation Of The Drug/Metabolite Potency Ratio
|
Modamio P, Jansat JM, Lastra CF, Mariño EL Change In The Analytical Error Function Depending On The Calibration Curve Range: Implications For Pharmacokinetic Parameter Estimation Of Carebastine.
|
V. Piotrovskij, V. Van de Velde, A. Van Pee Population Analysis Of Lubeluzole Pharmacokinetics In Healthy Volunteers And Patients With Ischaemic Stroke
|
M. du Preez1, J. Botha1, and L. McFadyen2 A Count Model For Analysing PK/PD Data For Theophylline In Neonatal Apnoea
|
Silvia Romano, A.C. Falcao Mª. del Mar Fdz. de Gatta, Mª. Victoria Calvo, Mª. Eugenia Méndez, Alfonso Domínguez-Gil, José M. Lanao Pharmacokinetics of amikacin in intensive care unit patients: population analysis.
|
M. Rosario1,4, C.A. Sharp2, D.I. Jodrell3, A.H. Thomson1 Population Pharmacokinetics Of Gentamicin In Oncology Patients
|
A. Rostami-Hodjegan, GT Tucker On estimating half-life using population pharmacokinetics
|
Lee P. Topping and Dr. Nicholas T. Longford An Alternative Definition Of Individual Bioequivalence
|
Tranchand B1, Pobel C2, Ardiet CJ1, Parola JN2, Ménard G2 Pharmacokinetic-Dynamic Modelling Of Neutropenic Effect Of Melphalan Using NONMEM Associated With A Cubic Spline Function
|
Iñaki F. Trocóniz1,2, Tarja Naukkarinen 3,4, Mats O. Karlsson4 Population Pharmacodynamic Modelling of Levodopa in Parkinsonian Patients Receiving the COMT Inhibitor Entacapone
|